Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 52%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is a global biopharmaceutical company that focuses on immunology, oncology, neuroscience, and aesthetics. With a strong portfolio of blockbuster drugs such as Humira, Skyrizi, and Rinvoq, acquisitions of Allergan, Cerevel, and ImmunoGen, and a robust pipeline, the company is poised for continued growth. Additionally, AbbVie's board-level Public Policy and Sustainability Committee ensures responsible pricing decisions and sustainable long-term strategy. Despite challenges such as government pricing pressures and product liability risks, the company has a strong track record of diversity and governance. With a buy rating and a price target of $261, AbbVie is a promising investment opportunity.

Bears say

AbbVie is facing biosimilar competition in the immunology segment, leading to potential erosion in sales of Humira, its flagship product. Despite acquired products in aesthetics and neuroscience, the company faces pipeline risks and patent challenges. With a P/E multiple of 15x, lower than peers, and a 16.5% EPS growth, the stock is trading at a discount, but the negative outlook is based on increasing competition and macro conditions leading to potential rotation away from defensive stocks.

AbbVie (ABBV) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 52% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 21 analysts, AbbVie (ABBV) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $281.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $281.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.